Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.

Arthritis Res Ther

Grace C Wright MD PC; Association of Women in Rheumatology; United Rheumatology, New York, NY, USA.

Published: November 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632073	PMC
http://dx.doi.org/10.1186/s13075-022-02940-5	DOI Listing

Publication Analysis

correction patient-reported

patient-reported outcomes

outcomes upadacitinib

upadacitinib versus

versus abatacept

abatacept patients

patients rheumatoid

rheumatoid arthritis

arthritis inadequate

inadequate response

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!